Automated Cell Culture Equipment Market Report 2026

The automated cell culture equipment market size has grown rapidly in recent years. It will grow from $2.32 billion in 2025 to $2.6 billion in 2026 at a compound annual growth rate (CAGR) of 11.9%. The growth in the historic period can be attributed to growth in pharmaceutical and biologics research, rising demand for consistent cell culture outcomes, expansion of drug discovery pipelines, increasing complexity of cell-based assays, early adoption of laboratory automation.

The automated cell culture equipment market size is expected to see rapid growth in the next few years. It will grow to $4.03 billion in 2030 at a compound annual growth rate (CAGR) of 11.6%. The growth in the forecast period can be attributed to increasing investments in regenerative medicine, expansion of cell and gene therapy pipelines, growing demand for scalable cell culture solutions, rising focus on reducing laboratory variability, increasing integration of ai-driven lab automation. Major trends in the forecast period include increasing deployment of fully automated cell culture platforms, rising adoption of high-throughput cell processing systems, growing integration of robotics and imaging technologies, expansion of closed-system and contamination-controlled workflows, enhanced focus on reproducibility and process standardization.

The growing adoption of personalized medicine is expected to drive the expansion of the automated cell culture equipment market in the coming years. Personalized medicine involves customizing medical treatments based on an individual’s genetic makeup, lifestyle, and environmental factors to deliver more accurate and effective care. The increased uptake of personalized medicine is driven by the ability to deliver more effective therapies, as treatments tailored to a patient’s genetic and biological profile lead to improved clinical outcomes. Automated cell culture equipment supports personalized medicine by enabling precise, scalable, and reproducible cell culture processes, which are essential for developing patient-specific therapies and conducting customized drug testing. For example, in February 2024, the Personalized Medicine Coalition, a US-based non-profit organization, reported that the FDA approved 16 new personalized treatments for rare diseases in 2023, a notable rise compared to six approvals in 2022. Therefore, the increasing adoption of personalized medicine is contributing to the growth of the automated cell culture equipment market.

Companies operating in the automated cell culture equipment market are increasingly prioritizing innovations that enable seamless workflow integration, such as closed single-use consumable systems, to improve process standardization, reduce contamination risks, limit manual intervention, and support efficient scaling from research to clinical manufacturing. Closed single-use consumable systems are sterile, disposable configurations that integrate multiple cell culture steps into a single unit, minimizing contamination and enabling consistent, reproducible workflows. For instance, in March 2025, Limula SA, a Switzerland-based biotechnology company focused on automated cell therapy manufacturing solutions, introduced LimONE, an integrated platform combining hardware, software, and single-use consumables to streamline and standardize cell culture and processing workflows. This launch represents the company’s first commercial product serving both research and GMP-compliant manufacturing environments. LimONE facilitates faster technology transfer, reduces labor and infrastructure costs, and supports scalable production of advanced cell therapies, including CAR-T and gene-edited stem cells. The system improves operational efficiency and ensures reproducibility across diverse cell therapy applications, reinforcing Limula’s position in the automated cell culture equipment market while supporting regulatory compliance.

In August 2023, Cell Microsystems, a US-based biotechnology company, acquired Fluxion Biosciences for an undisclosed amount. Through this acquisition, Cell Microsystems aims to broaden its portfolio of advanced cell analysis solutions by incorporating Fluxion Biosciences’ automated patch clamp and cell-based assay technologies, thereby enhancing capabilities in cellular electrophysiology and rare cell research. Fluxion Biosciences is a US-based company specializing in automated patch clamp systems and cell-based assay tools for advanced cellular analysis.

Major companies operating in the automated cell culture equipment market are F. Hoffmann-La Roche Ltd, Hitachi Ltd., Merck KGaA, Panasonic Holdings Corporation, Thermo Fisher Scientific Inc., Danaher Corporation, Becton Dickinson and Company, Corning Incorporated, Lonza Group AG, Olympus Corporation, Sartorius AG, Eppendorf SE, Tecan Group Ltd., STEMCELL Technologies Inc., Miltenyi Biotec B.V. & Co. KG, Hamilton Company, Greiner Bio-One International GmbH, Solida Biotech GmbH, Biostream International B.V., HiMedia Laboratories Pvt. Ltd., Kuhner Shaker AG, Cellexus International Ltd.

North America was the largest region in the automated cell culture equipment market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the automated cell culture equipment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the automated cell culture equipment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the automated cell culture equipment market by increasing costs of imported robotic arms, sensors, imaging modules, control software hardware, and precision instrumentation used in automated systems. Pharmaceutical and biotechnology companies in North America and Europe are most affected due to reliance on imported advanced laboratory equipment, while Asia-Pacific faces higher system acquisition costs. These tariffs are increasing capital investment requirements and extending procurement timelines. However, they are also driving local equipment manufacturing, regional assembly operations, and innovation in modular and scalable automation platforms.

The automated cell culture equipment market research report is one of a series of new reports that provides automated cell culture equipment market statistics, including automated cell culture equipment industry global market size, regional shares, competitors with a automated cell culture equipment market share, detailed automated cell culture equipment market segments, market trends and opportunities, and any further data you may need to thrive in the automated cell culture equipment industry. This automated cell culture equipment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Automated cell culture equipment refers to sophisticated laboratory systems developed to carry out cell cultivation, upkeep, and monitoring with minimal manual involvement. These systems combine technologies such as robotics, sensors, and software to improve reproducibility, efficiency, and accuracy in cell culture workflows. By automating routine operations, they support high-throughput experimentation, lower contamination risks, and enable advanced research in drug development, regenerative medicine, and other life science fields.

The main product types of automated cell culture equipment include instruments, consumables, and software. Instruments are advanced laboratory devices designed to automate essential cell culture processes such as seeding, incubation, monitoring, and harvesting, thereby enhancing consistency, efficiency, and scalability. These systems function at different levels of automation, including fully automated systems, semi-automated systems, and manual systems with automated features. Key applications include drug discovery and development, regenerative medicine, toxicology testing, vaccine development, and stem cell research, with major end users comprising pharmaceutical companies, biotechnology companies, academic and research institutes, contract research organizations (CROs), and diagnostic and testing laboratories.

The automated cell culture equipment market consists of sales of automated cell culture systems, bioreactors, incubators, cell counters, liquid handling systems, cell imaging systems, consumables, reagents, culture plates, flasks, pipettes, tubing sets, sensors, and microcarriers. Values in this market are ‘factory gate’ values; that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.